BioNTech (BNTX) has entered into two separate settlements with the US National Institutes of Health and the University of Pennsylvania over royalties on sales of the company's Covid-19 vaccine, separate filings showed Friday.
Without admitting liability, the biotechnology company said it agreed to pay $791.5 million to the NIH and $467 million to UPenn for, among others, claimed royalties from 2020 to 2023, according to the filings.
BioNTech also said Pfizer (PFE) agreed to reimburse $364.5 million of NIH's claimed royalties and up to $170 million of the amount payable to UPenn.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.